Education
About Us
Working with TipRanks
Follow Us
Alphamab Oncology (HK:9966)
:9966
9966 Stock Chart & Stats
HK$9.58
-HK$0.05(-1.46%)
At close: 4:00 PM EST
HK$9.58
-HK$0.05(-1.46%)
Day’s Range― - ―
52-Week RangeHK$4.18 - HK$15.75
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.94M
Market Cap
HK$8.70B
Enterprise ValueHK$7.33B
Total Cash (Recent Filing)HK$1.64B
Total Debt (Recent Filing)HK$273.48M
Price to Earnings (P/E)34.0
Beta1.67
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding974,293,700
10 Day Avg. Volume3,868,184
30 Day Avg. Volume3,937,702
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.76
Price to Sales (P/S)5.03
P/FCF Ratio16.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.65Price Target Upside42.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA >200% revenue jump and a move from HK$218.8M to HK$640.1M indicate strong product uptake or successful commercialization. Sustained top-line expansion strengthens R&D reinvestment capacity, supports scaling costs, and improves the odds of durable cash generation if conversion to operating cash follows.
High Gross MarginA 90.6% gross margin implies very efficient cost structure for core therapeutics, indicating pricing power or low COGS typical of biologics. High gross margins provide durable operating leverage, allowing incremental revenue to flow strongly to the bottom line as commercialization scales.
Strong Capital StructureVery high equity ratio and minimal leverage give the company financial flexibility to fund trials, commercial expansion, or strategic M&A without heavy interest burden. A healthy cash position offers a multi-month runway and resilience against biotech volatility.
Bears Say
Weak Cash GenerationZero operating and free cash flow despite reported profit signals fragile cash conversion from sales. Over months this forces reliance on financing, partnerships, or milestone receipts to fund R&D and commercialization, raising execution and liquidity risk during scale-up.
Moderate ROEA ~9% ROE shows positive but modest returns on shareholder capital for an innovator biotech. Over a multi-month horizon, this may reflect either early-stage reinvestment or suboptimal capital allocation and suggests limited efficiency in converting capital into superior shareholder returns.
Revenue Concentration On PartnershipsHeavy dependence on milestone/license and partnership revenue creates structural volatility tied to third-party timelines and trial readouts. Without steady direct sales expansion, predictable cash flows remain uncertain, constraining long-term planning and investment in independent commercialization.
Alphamab Oncology News
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$4.18 and its highest was HK$15.75 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$8.70B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Mar 31, 2026 which is in 37 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Aug 28, 2025. The company reported HK$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.023.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Undervalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 974,293,700 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of HK$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.393%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphamab Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.25%
12-Months-Change
Fundamentals
Return on Equity
13.34%
Trailing 12-Months
Asset Growth
12.28%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
9966 Stock 12 Month Forecast
Average Price Target
HK$13.65
▲(42.48% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
HBM Holdings Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Abbisko Cayman Limited
―
SinoMab Bioscience Ltd.
―
Options Prices
Currently, No data available
---